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Abstract
Although peptide vaccines have been actively studied in various animal models, their efficacy in treatment is limited. To
improve the efficacy of peptide vaccines, we previously formulated an efficacious peptide vaccine without carriers using the
natural phosphodiester bond CpG-DNA and a special liposome complex (Lipoplex(O)). Here, we show that immunization of
mice with a complex consisting of peptide and Lipoplex(O) without carriers significantly induces peptide-specific IgG2a
production in a CD4
+ cells- and Th1 differentiation-dependent manner. The transmembrane 4 superfamily member 5
protein (TM4SF5) has gained attention as a target for hepatocellular carcinoma (HCC) therapy because it induces
uncontrolled growth of human HCC cells via the loss of contact inhibition. Monoclonal antibodies specific to an epitope of
human TM4SF5 (hTM4SF5R2-3) can recognize native mouse TM4SF5 and induce functional effects on mouse cancer cells.
Pre-immunization with a complex of the hTM4SF5R2-3 epitope and Lipoplex(O) had prophylactic effects against tumor
formation by HCC cells implanted in an mouse tumor model. Furthermore, therapeutic effects were revealed regarding the
growth of HCC when the vaccine was injected into mice after tumor formation. These results suggest that our improved
peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive
tumors.
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Introduction
Peptide vaccines are pivotal for inducing and regulating
immune responses through their binding ability to the B cell
receptor and MHC as B-cell epitopes and T-cell epitopes.
Therefore, epitope-based peptide vaccines have gained attention
as potentially useful prophylaxis for cancers and infectious diseases
[1–4]. However, there is an important practical issue related to
this: the limited efficacy of peptide vaccines in the treatment of
humans. To improve the efficacy of peptide vaccines, liposomes
have been evaluated for delivery of vaccines [5–8], and adjuvants
such as flagella and CpG-DNA have been formulated to enhance
the magnitude of the immune responses [9–12].
Liposomes have been extensively evaluated as vehicles for
delivery in developing vaccines to enhance antibody production
and cytotoxic T lymphocytes (CTL) responses [8,13–15]. Encap-
sulated liposomes can protect antigens from the environment
and deliver them to target cells. Cationic liposomes such
as lipofectamin, 3b-[N-(N9,N9-dimethylaminoethane)-carbamoyl]-
cholesterol hydrochloride (DC-Chol), DC-Chol:phosphatidyl-b-
oleoyl-c-palmitoyl ethanolamine (DOPE), phosphatidylcholine:s-
tearylamine:cholesterol have been shown to improve CTL
response and antibody production [8]. In addition, pH-sensitive
liposomes such as DOPE:cholesterol hemisuccinate (CHEMS)
improve antigen delivery to the cytosol and the induction of CTL
responses [14]. Sterically stabilized cationic liposomes such as
DOPE:polyethylene glycol have also been used to increase the
uptake of antigen in immune cells [15].
CpG-DNA, which contains unmethylated CpG dinucleotides
flanked by specific base sequences and has immunostimulatory
activities, has been investigated as a potentially useful prophylactic
and therapeutic strategy [9,16,17]. CpG-DNA activates antigen-
presenting cells such as dendritic cells and B cells, and induces
Th1-biased immune responses and immunoglobulin (Ig) isotype
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as a potent adjuvant are enhanced by encapsulation in liposome
[5,21]. Several studies have indicated that phosphorothioate-
modified CpG-DNAs (PS-ODN), which is a sulfur substitution for
the nonbridging oxygens in the backbone providing its nuclease
resistance and efficient uptake into cells, induces backbone-related
side effects such as transient lymphoadenopathy, lymphoid follicle
destruction, arthritis, and PS-ODN-specific IgM production [22–
25]. Therefore, we identified the natural counterpart of the
phosphodiester bond CpG-DNA (PO-ODN, MB-ODN 4531(O))
from Mycobacterium bovis genomic DNA to induce optimal innate
immune responses without severe side effects [25,26]. Induction of
effective immune response is investigated in human and mouse cells
stimulated with MB-ODN 4531(O) encapsulated in a DOPE:-
CHEMS (1:1 ratio) complex (Lipoplex(O)) [27,28]. Furthermore,
complexes of B cell epitope peptide and Lipoplex(O) without
carriers significantly enhanced peptide-specific IgG production
depending on TLR9 [28].
The transmembrane 4 superfamily member 5 protein
(TM4SF5) has been implicated in hepatocellular carcinoma
(HCC) [29]. Previously, we screened the B cell epitope of the
hTM4SF5 protein and revealed the potent production of epitope-
specific antibodies in mice immunized with a complex of human
TM4SF5R2-3 peptide (hTM4SF5R2-3) and Lipoplex(O) [28]. We
also produced the monoclonal antibody by immunization with a
complex of antigenic peptide (hTM4SF5R2-3) and Lipoplex(O),
which has functional effects on human HCC cells (Huh-7)
expressing the antigen [28].
Here, we found that IgG production induced by a complex of B
cell epitope and Lipoplex(O) without carriers is dependent on
MHC, CD4
+ cells and Th1 differentiation. In addition, we report
that immunization with a complex of a specific B cell epitope of
hTM4SF5 protein and Lipoplex(O) protected mice from mouse
BNL 1ME A.7R.1 HCC (BNL-HCC) cell implantation. Our
results may be used for prophylaxis and therapy of HCC by the
development of an epitope-based peptide vaccine.
Materials and Methods
CpG-DNA
Natural phosphodiester bond CpG-DNA, specifically MB-
ODN 4531(O), was obtained from ST Pharm Co., Ltd [26].
MB-ODN 4531 consisted of 20 bases containing three CpG motifs
(underlined): AGCAGCGTTCGTGTCGGCCT.
Synthesis of B cell epitope peptides
The B cell epitope peptide of hTM4SF5 (hTM4SF5R2-3,
138NRTLWDRCEAPPRV
151) was described in earlier research
[28]. The B cell epitope peptide of mouse TM4SF5 (mTM4SF5R2-
3,
137NDTLWNLCEAPPHV
150) was selected on the basis of its
sequence homology. The peptides were produced by Peptron using
an automated peptide synthesizer (Peptron III-R24, Peptron). The
peptides werepurified byreverse-phaseHPLC (ProminenceHPLC,
Shimadzu Corp.) to a purity level that exceeded 95%. The peptide
was identified using a mass spectrometer (HP 1100 Series LC/
MSD, Hewlett-Packard).
Preparation of B cell epitope and CpG-DNA co-
encapsulated in DOPE:CHEMS complexes
The liposomes CHEMS and DOPE were purchased from
Sigma-Aldrich. Liposome complexes consisting of B cell epitope
and CpG-DNA (MB-ODN 4531(O)) co-encapsulated with
DOPE:CHEMS were prepared as reported previously [28,30].
Briefly, DOPE and CHEMS were mixed in 10% ethanol at a
molar ratio of 1:1, evaporated with nitrogen gas to make a solvent-
free lipid film, and resuspended in a mixture containing equal
volumes of water-soluble MB-ODN 4531(O) (50 mg/ml) and
peptide (50 mg/ml), followed by vigorous stirring at room
temperature for 30 min. After adjusting the pH to 7.0, the
complex of peptide and Lipoplex(O) was sonicated lightly for 30 s
with a sonicator (Soniifier 450, Branson Ultrasonics). After the
complex was filtered with a 0.22 mm filter, the complex was freeze-
thawed three times with liquid nitrogen.
Mice and immunization
We purchased four-week-old male C57BL/6 (H-2
d) and BALB/
c (H-2
b) mice from Central Lab. Animal, Inc., BALB/c TLR9
knockout mice from Oriental Bioservice, Inc., and BALB/c
STAT4 (Stat4
tm1Gru) and STAT6 (Stat6
tm1Gru) knockout mice, as
well as MHC class II knockout mice and OT-II transgenic mice
from Jackson Laboratory. Mice were maintained under specific-
pathogen-free conditions in a controlled environment (20–25uC,
32–37% humidity). All animal procedures performed in this study
are in accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Veterinary
Research & Quarantine Service of Korea. The protocol was
approved by the Institutional Animal Care and Use Committee of
Hallym University (Permit Number: Hallym 2009-52). The mice
were sacrificed under Zoletil 50+Rompun anesthesia, and all
efforts were made to minimize suffering. On three occasions at 10
day intervals, the mice were injected intraperitoneally (i.p.) with
50 mg of peptides supplemented with 50 mg of MB-ODN4531(O)
encapsulated in the DOPE:CHEMS complex (200 ml/mouse).
Anti-CD4 antibody treatment
Hybridoma GK1.5 (rat anti-mouse CD4 monoclonal antibody,
IgG2b) was obtained from the American Type Culture Collection
(ATCC). A sample of GK1.5 was produced in ascites and purified
by protein A column chromatography. A 100 mg sample of GK1.5
per mouse was injected four times i.p. on days 23, 21, 1, and 3
relative to the time of immunization. Blood samples were obtained
by orbital bleeding. The effective depletion of CD4
+ cells was
analyzed by FACSCalibur (Becton Dickinson) using anti-CD4
antibody, anti-CD8 antibody, and anti-CD3 antibody.
Measurement of IL-12
BALB/c mice, BALB/c STAT4 knockout mice and STAT6
knockout mice were injected i.p. with 50 mg of hTM4SF5R2-3
peptide supplemented with 50 mg of MB-ODN4531(O) encapsu-
lated in the DOPE:CHEMS complex (200 ml/mouse). After 24 h,
blood samples were obtained by orbital bleeding. The IL-12
amounts in the sera were then measured using commercially
available ELISA kits (R&D Systems).
Antigen-specific Ig ELISA assay
Mouse sera were achieved by orbital bleeding before each
injection as well as by sacrifice 10 days after final injection. To
determine the amounts and titers of total IgG, IgG1, and IgG2a,
96-well immunoplates (Nalgen Nunc International) were coated
with 5 mg/ml of each peptide and then blocked with 0.05% of
Tween-20 in PBS (PBST) containing 1% BSA. Total IgG, IgG1,
and IgG2a levels were measured as previously described [28].
Cross-reactivity of mouse anti-hTM4SF5 monoclonal
antibody: Competitive ELISA assay
Production of mouse monoclonal antibodies to the hTM4SF5
protein and the reactivity of the monoclonal antibodies were
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plates with 5 mg/ml of hTM4SF5R2-3 peptide and then blocked
them with PBST containing 1% BSA to obtain the titration curves
of anti-TM4SF5 antibody. The monoclonal antibodies were added
to the top row of each plate, and serial 1:4 dilutions in PBST were
then placed into subsequent rows. To perform a competition
assay, diluted monoclonal antibodies were preincubated with the
indicated amounts of mTM4SF5R2-3 peptide for 30 min and
then added to the wells of each plate. The plates were incubated
for 2 h at room temperature, washed with PBST, and then
incubated with detecting antibody such as anti-IgG antibody
conjugated with horseradish peroxidase for 2 h. A colorimetric
assay was developed with a TMB substrate solution, and the
absorbance at 450 nm was measured using a Spectra Max 250
microplate reader.
Cell culture
The mouse hepatoma cell lines BNL-HCC and H2.35 were
obtained from ATCC. BNL-HCC is a chemically transformed
mouse liver cell line derived from the normal BALB/c embryonic
liver cell line BNL CL2 [31]. The cells were cultured in DMEM
medium containing 10% FBS, 25 mM HEPES, 100 U/ml of
penicillin, and 100 mg/ml of streptomycin at 37uCi na n
atmosphere of 95% air and 5% CO2. H2.35 cells were cultured
at 33uC in an atmosphere of 90% air and 10% CO2. H2.35 is a
SV40 transformed mouse liver cell line derived from normal
BALB/c hepatocytes [32].
Detection of mouse TM4SF5 expression
To analyze the mTM4SF5 expression, we performed RT-PCR
and FACS analysis. Total RNAs were extracted with an RNeasy
Mini Kit (Qiagen), and the cDNA was generated as described
previously [33]. The standard PCR reaction was performed for 25
cycles with the following primer sets: mouse GAPDH, 59-AT-
GGTGAAGGTCGGTGTGAACG-39 and 59-GTTGTCATGG-
ATGATCTTGGCC-39(501 bp); mTM4SF5, 59-CGCTTAC-
TTGCGAAATGACA-39 and 59-TTTCCTGCAATCGCCACA-
CA-39 (174 bp). The expression of mTM4SF5 protein was
confirmed by FACS analysis with the purified anti-hTM4SF5
mAb.
MTT assay
To measure the growth of cells, an MTT assay was performed
with a 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT, Sigma-Aldrich) solution as described previously [34].
The growth of BNL-HCC cells and H2.35 cells treated with anti-
hTM4SF5 monoclonal antibody (5 mg/ml) for 5 days was
determined by MTT assay as reported previously [28]. The
MTT solution was added to each well at the indicated time
periods and the plates were incubated for an additional 4 h at
37uC. After the removal of the medium, the formazan crystals
were solubilized in DMSO. The color development was monitored
by means of a spectrophotometer at 595 nm with a reference
wavelength of 650 nm.
BrdU proliferation assay
We performed BrdU proliferation assay to investigate the cell
proliferation after treatment with anti-hTM4SF5 monoclonal
antibody. BNL-HCC and H2.35 cells were seeded into a 96-well
microplate at a density of 10
5 cells/well and then the cells were
treated with anti-hTM4SF5 monoclonal antibody (5 mg/ml) for
the indicated time periods. Subsequently, the cells were fixed,
washed, and incubated with primary and secondary antibodies
according to the instruction of CycLex BrdU Cellular ELISA Kit
(MBL International). The immune complexes were developed
with a substrate solution, and we used a Spectra Max 250
microplate reader (Molecular Devices) to measure the absorbance
at 450 nm.
Hepatocellular carcinoma mouse model
Four-week-old BALB/c mice or BALB/c TLR9 knockout mice
were injected i.p. with a complex of hTM4SF5R2-3 peptide
(50 mg/mouse) and Lipoplex(O) three times at 10 day intervals.
Ten days after the third immunization, the mice were inoculated
subcutaneously in the dorsal right flank with 5610
6 of BNL-HCC
cells in a 50% matrigel solution (HBSS/Matrigel, 1:1 v/v, BD
Biosciences) as previously described [35]. In order to evaluate the
therapeutic vaccination effect of the complex of hTM4SF5R2-3
peptide and Lipoplex(O) on a mouse tumor model, BALB/c mice
were inoculated subcutaneously in the dorsal right flank with
5610
6 of BNL-HCC cells in a 50% matrigel solution. The mice
were randomly divided into four treatment groups, after the tumor
size reached 5 mm in diameter. A complex of hTM4SF5R2-3
peptide (50 mg/mouse) and Lipoplex(O) was injected three times
at 10 days interval into the i.p. cavity. Size of the tumor was
measured 5 days interval with calipers in three dimensions, and
tumor volumes were calculated as width
26length/2. The mice
were sacrificed 60 days after tumor cell implantation, and the
tumors surgically excised and weighed. Mice were sacrificed when
the tumor size reached 2,000 mm
3 or the mice lost .20% of initial
body weight in accordance with the Guide for the Care and Use of
Laboratory Animals of the National Veterinary Research &
Quarantine Service of Korea to minimize suffering from a large
tumor burden. After the vaccination, the survival rate was
recorded for 100 days.
Histology and immunohistochemistry
For histopathological examination, tumors and organs were
removed and fixed in 4% buffered formalin solution, embedded in
paraffin by conventional methods, and cut into 4 mm thick
sections. The specimens were stained with hematoxylin and eosin.
To identify the expression of TM4SF5, the specimens were stained
with anti-TM4SF5 monoclonal antibodies using standard proce-
dures.
Statistics
Results are expressed as mean 6 standard deviation. Statistical
significance between two samples was performed using Student’s t
test. A p-value of ,0.05 was taken as statistically significant.
Survival analysis was performed using Kaplan-Meier method and
compared by log-lank test.
Results
Optimization for efficient production of epitope-specific
IgG with a complex of peptide epitope and Lipoplex(O)
Previously, we screened the B cell epitope of the hTM4SF5
protein and analyzed the production of IgG in the serum of
BALB/c mice injected i.p. with a complex of hTM4SF5R2-3
peptide and Lipoplex(O) [28]. To determine the optimal dose of
the peptide in the vaccination, we prepared complexes with
increasing amounts of hTM4SF5R2-3 peptide and Lipoplex(O).
When the mice were immunized with the complexes, it was noted
that the production of peptide-specific IgG was enhanced in a
peptide dose-dependent manner. Efficient IgG production is
obtained when we used 50 mg of peptide (Figure 1A). When we
used more than 50 mg of peptide, IgG production was not
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and liposome (data not shown). Next, we determined the efficient
injection protocol in a vaccination with a complex of
hTM4SF5R2-3 peptide and Lipoplex(O). As shown in Figure 1B,
the production of IgG was efficiently induced by simultaneous
immunization with a complex of the hTM4SF5R2-3 peptide and
Lipoplex(O).
Essential role of Th1 cells in IgG production induced by a
peptide epitope and Lipoplex(O)
To understand the immune response induced by a complex of B
cell epitope and Lipoplex(O) without carriers, we examined
whether or not the IgG production is dependent on MHC, CD4
+
cells and Th1 differentiation. First, we evaluated the requirement
of CD4
+ T cells. For the depletion of CD4
+ cells, anti-mouse CD4
monoclonal antibody (GK1.5) was injected four times i.p. using a
previously described method [36]. The CD4
+-depleted mice
(Figure 2A) revealed drastically reduced production of the
epitope-specific IgG (Figure 2B,C). Next, we observed the
involvement of MHC and TCR. The production of peptide-
specific IgG and IgG2a was also reduced in MHC class II
knockout mice with a CD4
+ deficiency (Figure 2D) and in OT-II
transgenic mice in which OVA-specific TCR transgenic CD4
+ T
cells are a major portion of the CD4
+ T cell population (Figure 2E).
Therefore, IgG production induced by a complex of B cell epitope
and Lipoplex(O) requires CD4
+ T cells, MHC, and TCR. The
production of OVA-specific-IgG was also reduced in MHC class II
knockout mice (Figure S1); OT-II transgenic mice produced
OVA-specific-IgG antibodies at titers comparable to wild-type
mice (Figure S2).
Furthermore, we examined the involvement of Th1 differenti-
ation in peptide-specific IgG production. Previous reports showed
that the Th1 responses are associated with production of IgG2a
antibody, while the Th2 responses are associated with switching to
the IgG1 isotype [37,38]. STAT4 is required in the immune
responses for IL-12-mediated IFN-c production [38,39]. There-
fore, STAT4 wild type mice produced significantly higher level of
IgG2a compared with STAT4 knockout mice [40]. In STAT6
knockout mice, highly significant decrease in the level of IgG1
isotype was reported [38,41]. The fact that IgG and IgG2a
production was reduced in STAT4 knockout mice reveals that, in
response to immunization, STAT4 promotes the differentiation of
T cells into Th1 cells (Figure 3A). However, as shown in Figure 3B,
STAT6 knockout has no effect on IgG (IgG2a) production. These
results suggest that Th1 cells play an essential role in IgG (IgG2a)
production induced by a complex of the B cell epitope and
Lipoplex(O). We also observed that the level of IL-12 induced by a
complex of B cell epitope and Lipoplex(O) was decreased in the
sera of STAT4 knockout mice compared with the wild type mice.
However, STAT6 knockout mice produced higher amounts of IL-
12 by a complex of B cell epitope and Lipoplex(O) compared with
the wild type mice (Figure 3C) as reported previously [42,43].
Effect of anti-hTM4SF5 monoclonal antibody on mouse
hepatocellular carcinoma cells in vitro
Previously, we evaluated the functional effects of anti-
hTM4SF5R2-3-specific monoclonal antibody produced by immu-
nization with a complex of hTM4SF5R2-3 peptide and Lipo-
plex(O) on antibody-mediated hTM4SF5 targeting in human
HCC cells [28]. To evaluate the prophylactic efficacy of a vaccine
containing the complex of hTM4SF5R2-3 peptide and Lipo-
plex(O) on a HCC mouse model, we examined the functional
effects of anti-hTM4SF5R2-3 monoclonal antibody on mouse
HCC cells. Clustal W analysis revealed that hTM4SF5 and
mTM4SF5 share 82% similarity (Figure S3). We first identified the
expression of mTM4SF5 and confirmed the functional effects of
anti-hTM4SF5R2-3 peptide monoclonal antibody in mouse HCC
cells. The expression of mTM4SF5 was detected in the BNL-HCC
cell line at the mRNA level (Figure 4A). The anti-hTM4SF5R2-3
peptide monoclonal antibody was bound to BNL-HCC cells,
demonstrating cross-reactivity of anti-hTM4SF5R2-3 peptide
monoclonal antibody to mTM4SF5 protein (Figure 4B). To
confirm that anti-hTM4SF5R2-3 peptide monoclonal antibody
targets the mTM4SF5 protein, we used an ELISA test which
determined that anti-hTM4SF5R2-3 peptide monoclonal anti-
body reacted with the hTM4SF5R2-3 peptide as well as with the
mTM4SF5R2-3 peptide (Figure 4C). To consider the effect of the
anti-hTM4SF5R2-3 peptide monoclonal antibody on mouse HCC
Figure 1. Production of IgG by immunization with a complex of hTM4SF5R2-3 peptide and Lipoplex(O). A. Optimal dose of peptide in
the complex of hTM4SF5R2-3 peptide and Lipoplex(O). BALB/c mice (n=3/group) were immunized with increasing amounts of hTM4SF5R2-3 peptide
and Lipoplex(O) complex. B. Effect of the injection protocol. We immunized one group of mice with hTM4SF5R2-3 peptide after injection with
Lipoplex(O) (Lipoplex(O)/TM4SF5R2-3) and another group with MB-ODN 4531(O) after injection with hTM4SF5R2-3 peptide and the DOPE:CHEMS
complex (DOPE:CHEMS+TM4SF5/4531(O)) three times with a 10 day interval (n=3/group). The sera were collected, and titers of the peptide-specific
total IgG were assayed with an ELISA kit. These experiments were performed 3 times with similar results. **P,0.01 (vs PBS control).
doi:10.1371/journal.pone.0033121.g001
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anti-hTM4SF5R2-3 peptide monoclonal antibody delayed the
growth of BNL-HCC cells. In contrast, there was no effect on the
growth of H2.35 cells which did not express mTM4SF5
(Figure 4D). We then investigated the effects of the anti-
hTM4SF5R2-3 peptide antibody on DNA synthesis using the
BrdU incorporation assay. The rate of DNA synthesis in BNL-
HCC cells treated with anti-hTM4SF5R2-3 peptide monoclonal
antibody was reduced in five days by approximately 40%
compared to normal IgG treated-BNL-HCC cells. However,
there was no significant reduction in the rate of DNA synthesis of
H2.35 cells (Figure 4E).
Prophylactic efficacy of a vaccine containing a hTM4SF5
epitope and Lipoplex(O) complex against tumor
formation by hepatocellular carcinoma cells implanted in
mice
To evaluate the prophylactic efficacy of the vaccine containing
the complex of hTM4SF5R2-3 peptide and Lipoplex(O) on tumor
formation, we implanted BNL-HCC cells into BALB/c mice 10
days after vaccination three times. As a negative control, two
groups of mice were immunized with PBS or hTM4SF5R2-3
peptide encapsulated in DOPE:CHEMS, followed by implanta-
tion with BNL-HCC cells. We observed significant production of
hTM4SF5R2-3 peptide-specific antibody in response to implan-
tation in the mice immunized with the complex of hTM4SF5R2-3
peptide and Lipoplex(O) (Figure 5A). BNL-HCC cells implanted
into BALB/c mice grew continuously into a tumor mass, whereas
tumor development was significantly inhibited in the vaccinated
mice (Figure 5B–D). Vaccination with DOPE:CHEMS and
TM4SF5R2-3 induced production of hTM4SF5R2-3 peptide-
specific antibody at a low level and showed weak prophylactic
activity. Vaccination did not affect the body weight of the
mice during the experiment, suggesting that no significant side
effects were provoked by immunization with the complex of
hTM4SF5R2-3 peptide and Lipoplex(O) (Figure 5E). The
expression of TM4SF5 in HCC tumor tissue was confirmed by
immunohistochemistry; specifically, the tumor cells were inten-
sively immunostained by anti-hTM4SF5R2-3 peptide monoclonal
Figure 2. Contribution of CD4
+ T cell on IgG production. A–C. Transient depletion of CD4
+ cells prevents IgG production. GK1.5 (anti-CD4
antibody) (n=3/group) was injected i.p to deplete CD4
+ cells (A). Normal IgG was used as a control. The mice were immunized with hTM4SF5R2-3
peptide and Lipoplex(O) complex. The sera were collected, and titration curves (B) and amounts (C) of the peptide-specific total IgG were assayed
with an ELISA kit. D. Defect in CD4
+ T cell activation in MHC class II2/2 mice prevents IgG production. C57BL/6 mice and C57BL/6 MHC class II2/2
mice (n=3/group) were injected i.p. with the hTM4SF5R2-3 peptide and Lipoplex(O) complex. E. Defect in specific CD4
+ T cell activation prevents IgG
production in OT-II transgenic mice. C57BL/6 mice and C57BL/6 OT-II transgenic mice (OT-II TG) (n=3/group) were injected i.p. with the hTM4SF5R2-3
peptide and Lipoplex(O) complex. These experiments were performed 3 times with similar results. Each bar is expressed as the Mean 6 SD of three
mice. **P,0.01.
doi:10.1371/journal.pone.0033121.g002
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there was no significant prevention of tumor development in the
TLR92/2 mice (Figure 6), which are defective in IgG production
(Figure 6A), after immunization with the complex of
hTM4SF5R2-3 peptide and Lipoplex(O) [28]. Interestingly, the
tumor growth was lower in the TLR92/2 mice than in wild type
mice (Figure 5B–D vs Figure 6B–D). We conclude that a complex
of hTM4SF5R2-3 peptide and Lipoplex(O) was effective in
eliciting a protective immune response via the generation of
specific antibodies that bind to TM4SF5 protein and inhibit tumor
growth in vivo.
Therapeutic efficacy of vaccine containing a hTM4SF5
epitope and Lipoplex(O) complex on the growth of
hepatocellular carcinomas in mice
To evaluate the therapeutic antitumor effects in tumor-bearing
mice after vaccination with a complex of hTM4SF5R2-3 peptide
and Lipoplex(O), we implanted BALB/c mice with BNL-HCC
cells and then vaccinated them with a complex of hTM4SF5R2-3
peptide and Lipoplex(O) after 25 days. Mice vaccinated with the
complex of hTM4SF5R2-3 peptide and Lipoplex(O) produced
significantly higher amounts of hTM4SF5R2-3 peptide-specific
antibody (Figure 7A), and significantly reduced tumor growth
(Figure 7B–D) compared to the other controls. PBS-treated mice
started to die 65 days after BLN-HCC implantation, with 100% of
them expiring by 80 days. However, the mice vaccinated with the
complex of hTM4SF5R2-3 peptide and Lipoplex(O) demonstrat-
ed prolonged survival up to 100 days post-tumor implantation
(Figure 8). Thus, our data indicate that vaccination with a complex
of hTM4SF5R2-3 peptide and Lipoplex(O) in HCC-bearing mice
has therapeutic antitumor effects.
Discussion
Several investigators have reported that CpG-DNA has Th1-
responsive immunoadjuvant effects and that its potent immuno-
adjuvant effects are augmented by liposome encapsulation
[5,12,15,16,21]. Suzuki et al. showed that CpG-DNA encapsulated
in cationic liposomes induces the expression of IL-12 and IFN-c
and that CpG-DNA-liposome co-encapsulated with ovalbumin
(OVA) caused the induction of OVA-specific CTLs, which
exhibited potent cytotoxicity against OVA-expressing tumor
[21]. In addition, SSCL improves the uptake by B cells, dendritic
cells, and macrophages, and the co-encapsulation of CpG-DNA
with OVA magnified Ag-specific IFN-c and IgG production [15].
Furthermore, Li et al. found that CpG-DNA and HER-2/neu-
derived peptide co-encapsulated in DSPC/Chol liposomes
enhances the CTL response and IgG production [12]. Previously,
we formulated an efficacious peptide vaccine without carriers
using the natural phosphodiester bond CpG-DNA (MB-ODN
4531(O)) and a special liposome (DOPE:CHEMS) complex
(Lipoplex(O)) to improve the efficacy of peptide vaccines. We
showed that immunization of BALB/c mice with a complex
consisting of B cell epitope peptide and Lipoplex(O) resulted in a
markedly greater abundance of epitope-specific IgG than that in
mice immunized with B cell epitope peptide and MB-ODN
4531(O) co-encapsulated in other liposomes [28]. In this report,
we presented the optimal dose of the peptide and an efficient
injection protocol in vaccinations with a complex of hTM4SF5R2-
3 peptide and Lipoplex(O). Efficient IgG production was obtained
with 50 mg of peptide and simultaneous immunization with the
hTM4SF5R2-3 peptide and Lipoplex(O) complex (Figure 1).
We also observed that the production of antibodies by
immunization with a complex of B cell epitope peptide and
Figure 3. Contribution of Th1 differentiation on IgG produc-
tion. STAT4 but not STAT6 is required for IgG production by a complex
of peptide and Lipoplex(O). A,B. BALB/c mice, BALB/c STAT42/2 mice
(A), and BALB/c STAT62/2 mice (B) (n=3/group) were injected i.p.
three times with a 10 day interval with the hTM4SF5R2-3 peptide and
Lipoplex(O) complex. The sera were collected, and the amounts of the
peptide-specific total IgG, IgG1, and IgG2a were assayed with an ELISA
kit. These experiments were performed 3 times with similar results. C.
BALB/c mice, BALB/c STAT42/2 mice, and BALB/c STAT62/2 mice
(n=5/group) were injected i.p with hTM4SF5R2-3 peptide and
Lipoplex(O) complex, and sera from the mice were harvested at 24 h
after injection. The levels of IL-12 in the serum were measured with an
ELISA assay. Each bar is expressed as the Mean 6 SD of three mice.
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0033121.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33121Figure 4. Effects of anti-hTM4SF5 monoclonal antibody on mouse HCC cells. A. The expression levels of mTM4SF5 mRNA in the indicated
mouse HCC cell lines and normal mouse hepatocytes were analyzed by RT-PCR. B. Detection of mTM4SF5 in BNL-HCC cells and H2.35 cells by anti-
hTM4SF5R2-3 peptide monoclonal antibody according to a FACS analysis. Normal mouse IgG was used as a control. C. Reactivity of anti-hTM4SF5R2-
3 monoclonal antibody with the mTM4SF5R2-3 peptide. The hTM4SF5R2-3 peptide was immobilized on a plate, and competitive ELISA was
performed using increasing amounts of soluble mTM4SF5R2-3 peptide. D. Effect of anti-hTM4SF5R2-3 peptide monoclonal antibody on the growth
of BNL-HCC cells and H2.35 cells. Cell growth was measured by an MTT assay. E. Effect of anti-hTM4SF5R2-3 peptide monoclonal antibody on the
proliferation of BNL-HCC cells and H2.35 cells. The DNA synthesis activity was monitored by BrdU incorporation assay. Each bar is expressed as the
Mean 6 SD of three experiments. **P,0.01.
doi:10.1371/journal.pone.0033121.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33121Figure 5. Prophylactic efficacy of a vaccine containing hTM4SF5R2-3 peptide and Lipoplex(O) complex in HCC implanted mouse.
BALB/c mice were immunized with a complex of hTM4SF5R2-3 peptide and Lipoplex(O). The immunized mice were implanted with the BNL-HCC cells
(n=12 per group; n=10 per PBS-treated control). A. Induction of a strong serologic response to BNL-HCC cell implantation by vaccination with
epitope and Lipoplex(O). The sera were collected, and the amounts of mTM4SF5R2-3 peptide-specific total IgG were assayed using an ELISA kit. Each
bar is expressed as the Mean 6 SD of 10 or 12 mice. B–D. Tumor formation in mice implanted with BNL-HCC cells was inhibited by vaccination with
the hTM4SF5R2-3 peptide and Lipoplex(O) complex 60 days after the implantation of BNL-HCC cells. Tumor volumes were calculated as
(length6width
2)/2 (B). Macroscopic appearance of HCC tumor tissues (C). Tumor growth was measured by tumor weight (D). E. Body weights were
measured at the indicated time intervals. F. Histology of normal liver and tumor tissue derived from BNL-HCC cell-implanted mice was observed by
staining with hematoxylin and eosin (H&E, left panel). An immunohistochemical analysis (IHC) was performed with anti-hTM4SF5R2-3 monoclonal
antibody (right panel). TM4SF5 positive area was expressed as brown color. Scale bars, 500 mm. **P,0.01.
doi:10.1371/journal.pone.0033121.g005
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33121Lipoplex(O) required MHC, CD4
+ cells and Th1 differentiation
(Figure 2). Although the Th1 immune response was essential for
peptide-specific IgG production mediated by Lipoplex(O), the
mechanism that induces the peptide-specific Th1 response remains
to be investigated in detail. Further study is also needed to
investigate whether or not IgG production induced by a complex
Figure 6. Involvement of TLR9 on prophylactic efficacy of a vaccine containing hTM4SF5R2-3 peptide and Lipoplex(O) complex.
BALB/c TLR92/2 mice were immunized with a complex of hTM4SF5R2-3 peptide and Lipoplex(O) and the mice were implanted with the BNL-HCC
cells (n=8 per group). A. Effect of TLR9 on serologic response to BNL-HCC cell implantation after vaccination with epitope and Lipoplex(O). The sera
were collected, and the amounts of mTM4SF5R2-3 peptide-specific total IgG were assayed using an ELISA kit. Each bar is expressed as the Mean 6 SD
of 8 mice. B. Tumor volumes were calculated as width
26length/2. The tumor volumes in TLR92/2 mice were compared with the tumor volumes in
wild type BALB/c mice in Figure 5B. C. Macroscopic appearance of HCC tumor tissues. D. Tumor growth was measured by tumor weight. E. Body
weights were measured at the indicated time intervals. F. Histology of normal liver and tumor tissue derived from BNL-HCC cell-implanted mice was
observed by staining with hematoxylin and eosin (left panel). An immunohistochemical analysis was performed with anti-hTM4SF5R2-3 monoclonal
antibody (right panel). TM4SF5 positive area was expressed as brown color. Scale bars, 500 mm.
doi:10.1371/journal.pone.0033121.g006
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33121Figure 7. Therapeutic efficacy of a vaccine containing hTM4SF5R2-3 peptide and Lipoplex(O) complex in HCC implanted mouse. A.
Induction of a strong serologic response by vaccination with the hTM4SF5R2-3 peptide and Lipoplex(O) complex or indicated combinations after
BNL-HCC cell implantation in mice (n=12 per hTM4SF5R2-3 peptide+Lipoplex(O) group; n=8 per PBS-treated control group, Lipoplex(O) group, and
DOPE:CHEMS+hTM4SF5R2-3 peptide group). The sera were collected 10 days after vaccination, and the amounts of mTM4SF5R2-3 peptide-specific
total IgG were assayed using an ELISA kit. Each bar is expressed as the Mean 6 SD of 8 or 12 mice. B–D. Inhibition of tumor formation in mice
vaccinated with the hTM4SF5R2-3 peptide and Lipoplex(O) complex 60 days after the implantation of BNL-HCC cells. Tumor volumes were calculated
as width
26length/2 (B). Macroscopic appearance of HCC tumor tissues (C). Tumor growth was measured by tumor weight of the surviving mice (D).
E. Body weights were measured at the indicated time intervals. Each bar represents the Mean 6 SD of 8 or 12 mice. *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0033121.g007
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33121of B cell epitope and Lipoplex(O) is dependent on the MHC type
and if a novel mechanism is involved.
Several uniquely over-expressed antigens, including TM4SF5
[29] and glypican-3 [44], have been linked to the pathogenesis of
HCC. Recently, glypican-3-derived peptide vaccine was investigat-
ed to determine its ability to induce HCC-specific CTLs [45]. The
mRNA expression of TM4SF5 in human cancer is prevalently
observed in pancreatic cancer, soft tissue csarcoma, gastric cancer,
carcinoma of the papilla vateri, and colon cancer [46]. When the
TM4SF5 overexpression in human HCC specimens was examined
byimmunohistochemicalstaining,theTM4SF5wasdetected in7of
9 HCC tissues in the cell membrane and cytosol whereas normal
liver tissues were not positive for TM4SF5 expression [29].
Therefore, TM4SF5 is presumed to be a novel molecular target
for the clinical development of a type of HCC immunotherapy
[47,48]. Here, we analyzed whether the monoclonal antibody
produced by immunization with a complex of hTM4SF5R2-3
peptide and Lipoplex(O) can detect TM4SF5 in tumor tissues
derived from a HCC mouse model (Figure 5F and 6F).
Lee et al. reported that TM4SF5 is important in HCC
formation by inducing morphological elongation, epithelial-
mesenchymal transitions, abnormal cell growth in vitro, and tumor
formation in vivo [29]. Overexpression of TM4SF5 in HCC cells
leads to S phase progression by shortening the G1 phase period
and the cells continuously proliferate under confluent conditions.
The overexpression of TM4SF5 also enhances the cytosolic
p27
kip1 stability and inactivates the RhoA pathway, resulting in
loss of contact inhibition through actin reorganization [29].
Activation of c-Jun N-terminal kinase (JNK) pathway associates
with the ser10 phosphorylation and cytosolic localization of
p27
kip1 in the TM4SF5-expressing cells [49]. Furthermore,
physical association between TM4SF5 and integrin is also capable
of modulating the signaling properties of integrins [50]. Previously,
we showed that the monoclonal antibody produced by immuni-
zation with a complex of hTM4SF5R2-3 peptide and Lipoplex(O)
had functional effects on human HCC cell line (Huh-7 cells)
expressing the antigen. The anti-hTM4SF5R2-3 peptide-specific
antibody can detect native protein and induce functional changes
(delay of the cell growth) in Huh-7 cells, which suggest a possible
application in therapeutics [28]. Here, we investigated further that
growth of mouse HCC cell line (BNL-HCC) expressing hTM4SF5
was markedly delayed by the antibody treatment but not in H2.35
cells which did not express hTM4SF5 (Figure 4). However, further
study is needed to investigate the functional role of anti-
hTM4SF5R2-3 monoclonal antibody in TM4SF5-mediated cell
growth, which may support the future application of the antibody
in HCC therapeutics. In agreement with the in vitro data, humoral
immune responses elicited by active immunization with a complex
of hTM4SF5R2-3 peptide and Lipoplex(O) prevented tumor
development in a HCC mouse model (Figure 5). We also found
that a complex of TM4SF5R2-3 peptide and Lipoplex(O) in
HCC-bearing mice can reduce HCC tumor growth even after
tumor formation (Figure 7). This is therefore a therapeutic HCC
vaccine candidate.
TLR9 recognizes bacterial DNA and CpG-DNA as non-self
DNA in response to bacterial invasion. The activation of TLR9
induces a strong Th1 immune response with upregulation of Th1
cytokines, costimulatory molecules and MHC molecules [17]. The
enhanced Th1 responses by IL-12 and IFN-c production
contribute to the protection of the host from infectious pathogens
[51,52]. The antiviral activity against the DNA virus murine CMV
in vivo was diminished in TLR9 knockout mice [53]. Furthermore,
TLR9 knockout mice had reduced ability to clear the Gram-
positive bacterial pathogen Streptococcus pneumoniae and Gram-
negative bacterial pathogen Klebsiella pneumoniae [54,55]. Interest-
ingly, we observed that the HCC tumor growth was lower in the
TLR92/2 mice than in wild type mice (Figure 6). As the
relevance of TLR9 to the tumor formation is not known yet,
further study is needed to clarify this issue.
Our overall results show that IgG production induced by a
complex of B cell epitope and Lipoplex(O) without carriers is
dependent on MHC, CD4
+ cells and Th1 differentiation.
Furthermore, this study demonstrates that vaccination with a
complex of hTM4SF5R2-3 peptide and Lipoplex(O) can reduce a
hepatocellular carcinoma mass in the HCC mouse model.
Therefore, our strategy involving the use of the hTM4SF5R2-3
peptide may provide a novel prophylaxis measure and therapy for
HCC patients with TM4SF5-positive tumors.
Supporting Information
Figure S1 MHC class II is required for IgG production
(data correspond to Figure 2D). C57BL/6 mice (WT) and
C57BL/6 MHC class knockout mice (MHC-II2/2)( n = 3 /
group) were immunized with an OVA and IFA mixture. The sera
were collected, and titers of OVA-specific total IgG, IgG1, and
IgG2a were assayed with an ELISA kit. These experiments were
performed 3 times with similar results. **P,0.01.
(TIF)
Figure S2 T cell activation is required for IgG produc-
tion (data correspond to Figure 2E). C57BL/6 mice and
C57BL/6 OT-II transgenic mice (OT-II TG) (n=3/group) were
immunized with an OVA and IFA mixture. The sera were
collected, and titers of OVA-specific total IgG were assayed with
an ELISA kit. These experiments were performed 3 times with
similar results.
(TIF)
Figure S3 CLUSTAL alignment of hTM4SF5 and
mTM4SF5. The location of the TM4SF5R2-3 epitopes is shown.
(TIF)
Figure 8. Survival rate of tumor-bearing mice. BALB/c mice were
immunized with the hTM4SF5R2-3 peptide and Lipoplex(O) complex or
indicated combinations after BNL-HCC cell implantation in mice (n=12
per group; n=10 per PBS-treated control). After the vaccination, the
survival rate was recorded for 100 days.
doi:10.1371/journal.pone.0033121.g008
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